Septerna is a biotech firm unlocking diverse drug discovery potential in G protein-coupled receptors across various diseases.
Septerna has raised $150.0M in total funding. The most recent round was Series B. The last funding was announced in July 2023.
Septerna's investors include RA Capital Management, Catalio Capital Management, Samsara BioCapital, Third Rock Ventures, Soleus Capital.
Septerna is headquartered in San Francisco, United States.
Septerna is a biotech firm unlocking diverse drug discovery potential in G protein-coupled receptors across various diseases.
Septerna is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Septerna — Funding & Investors." VCBacked, July 11, 2023, https://www.vcbacked.co/company/septerna. Accessed November 11, 2026.
VCBacked. (2023). Septerna — Funding & Investors. Retrieved November 11, 2026, from https://www.vcbacked.co/company/septerna
{{cite web |title=Septerna — Funding & Investors |url=https://www.vcbacked.co/company/septerna |website=VCBacked |access-date=November 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Septerna? Request a listing update